Table 4.
Multivariate predictors of vaccine deliberation or vaccine reluctance regarding intent to be vaccinated, according to multinomial model, based on last survey response (N = 752).*
| Vaccine deliberative (“undecided” vs. “yes/received”) |
Vaccine reluctant (“no” vs. “yes/received”) |
|||||
|---|---|---|---|---|---|---|
| Characteristic | aOR† | 95% CI | P-value | aOR | 95% CI | P-value |
| Age group | ||||||
| 18–49 y | 1.03 | 0.41–2.62 | 0.947 | 1.75 | 0.72–4.24 | 0.215 |
| 50–64 y | 0.72 | 0.26–1.94 | 0.511 | 0.90 | 0.34–2.33 | 0.824 |
| ≥ 65 y | Reference | Reference | ||||
| Race | ||||||
| American Indian/ Alaska Native | 1.98 | 0.61–6.49 | 0.257 | 3.20 | 1.13–9.02 | 0.028 |
| Asian | 0.34 | 0.08–1.52 | 0.157 | 0.63 | 0.20–1.94 | 0.418 |
| Black/African American | 1.69 | 1.02–2.78 | 0.040 | 2.47 | 1.57–3.88 | <0.001 |
| Multiple | 0.94 | 0.36–2.41 | 0.892 | 2.41 | 1.17–4.96 | 0.017 |
| Native Hawaiian/ Pacific Islander | 1.01 | 0.35–2.88 | 0.987 | 1.32 | 0.54–3.25 | 0.540 |
| White | Reference | Reference | ||||
| Ethnicity | ||||||
| Hispanic or Latino | 1.29 | 0.59–2.82 | 0.524 | 0.50 | 0.21–1.20 | 0.120 |
| Non-Hispanic or Latino | Reference | Reference | ||||
| Sex | ||||||
| Female | 2.26 | 1.42–3.60 | 0.001 | 1.45 | 0.96–2.17 | 0.076 |
| Male | Reference | Reference | ||||
| Participant type | ||||||
| Resident | 1.41 | 0.68–2.91 | 0.358 | 1.96 | 1.00–3.83 | 0.048 |
| Staff | Reference | Reference | ||||
| Highest education level | ||||||
| Less than high school | 3.90 | 1.46–10.36 | 0.006 | 3.51 | 1.54–8.03 | 0.003 |
| High school / GED | 4.69 | 2.06–10.69 | <0.001 | 3.34 | 1.63–6.86 | 0.001 |
| Some college | 4.56 | 2.03–10.27 | <0.001 | 3.38 | 1.66–6.90 | 0.001 |
| Bachelors or higher | Reference | Reference | ||||
| Employed | ||||||
| Yes | 1.43 | 0.76–2.68 | 0.269 | 1.11 | 0.63–1.93 | 0.723 |
| No | Reference | Reference | ||||
| Underlying medical conditions (≥1)‡ | ||||||
| Yes | 1.36 | 0.84–2.21 | 0.211 | 0.77 | 0.48–1.23 | 0.268 |
| No | Reference | Reference | ||||
| Enrollments per unique participant | ||||||
| 2 | 0.79 | 0.40–1.56 | 0.496 | 0.54 | 0.29–0.99 | 0.045 |
| 3–5 | 1.02 | 0.57–1.83 | 0.949 | 1.05 | 0.64–1.71 | 0.846 |
| ≥6 | 1.23 | 0.69–2.18 | 0.488 | 0.76 | 0.45–1.28 | 0.304 |
| 1 | Reference | Reference | ||||
| Prior SARS-CoV-2 positive test | ||||||
| Yes | 0.63 | 0.29–1.36 | 0.242 | 0.50 | 0.25–1.00 | 0.049 |
| No | Reference | Reference | ||||
| Received flu vaccine | ||||||
| Yes | 0.43 | 0.27–0.67 | <0.001 | 0.36 | 0.24–0.53 | <0.001 |
| No | Reference | Reference | ||||
*
Based on complete case responses (N = 752); responses “yes” or “received vaccine” combined is the reference group for the outcome.
†
aOR = adjusted odds ratio.
‡
Underlying conditions include asthma, blood disorders, cancer, chronic obstructive pulmonary disease or emphysema, immunosuppression, liver disease, heart disease, diabetes, neurologic conditions or aspirin therapy.